vs
ABVC BIOPHARMA, INC.（ABVC）与Alpha Cognition Inc.（ACOG）财务数据对比。点击上方公司名可切换其他公司
Alpha Cognition Inc.的季度营收约是ABVC BIOPHARMA, INC.的3.5倍（$2.8M vs $796.0K）。Alpha Cognition Inc.净利率更高（-245.5% vs -256.6%，领先11.1%）
ABVC生物制药是一家处于临床阶段的生物制药企业，专注于开发肿瘤、眼科、中枢神经系统疾病等领域的创新治疗方案，业务覆盖北美及亚洲主要市场，多款自研候选药物正处于临床试验推进阶段。
ABVC vs ACOG — 直观对比
营收规模更大
ACOG
是对方的3.5倍
$796.0K
净利率更高
ACOG
高出11.1%
-256.6%
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $796.0K | $2.8M |
| 净利润 | $-2.0M | $-6.9M |
| 毛利率 | 100.0% | — |
| 营业利润率 | -246.8% | -283.7% |
| 净利率 | -256.6% | -245.5% |
| 营收同比 | 104.5% | — |
| 净利润同比 | -417.4% | — |
| 每股收益（稀释后） | $-0.09 | $-0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABVCACOG
| Q4 25 | — | $2.8M | ||
| Q3 25 | $796.0K | $2.8M | ||
| Q2 25 | — | $1.7M | ||
| Q1 25 | — | $2.9M | ||
| Q4 24 | $2.0K | — | ||
| Q3 24 | $389.3K | — | ||
| Q2 24 | $117.1K | — | ||
| Q1 24 | $1.2K | — |
净利润ABVCACOG
| Q4 25 | — | $-6.9M | ||
| Q3 25 | $-2.0M | $-1.3M | ||
| Q2 25 | — | $-10.5M | ||
| Q1 25 | — | $-2.0M | ||
| Q4 24 | $-731.6K | — | ||
| Q3 24 | $-394.8K | — | ||
| Q2 24 | $-942.3K | — | ||
| Q1 24 | $-2.8M | — |
毛利率ABVCACOG
| Q4 25 | — | — | ||
| Q3 25 | 100.0% | — | ||
| Q2 25 | — | 96.7% | ||
| Q1 25 | — | 99.6% | ||
| Q4 24 | 100.0% | — | ||
| Q3 24 | 99.9% | — | ||
| Q2 24 | 99.8% | — | ||
| Q1 24 | 77.0% | — |
营业利润率ABVCACOG
| Q4 25 | — | -283.7% | ||
| Q3 25 | -246.8% | -187.0% | ||
| Q2 25 | — | -346.1% | ||
| Q1 25 | — | -125.9% | ||
| Q4 24 | -35837.4% | — | ||
| Q3 24 | -77.7% | — | ||
| Q2 24 | -734.2% | — | ||
| Q1 24 | -235539.8% | — |
净利率ABVCACOG
| Q4 25 | — | -245.5% | ||
| Q3 25 | -256.6% | -46.4% | ||
| Q2 25 | — | -632.7% | ||
| Q1 25 | — | -68.5% | ||
| Q4 24 | -37211.3% | — | ||
| Q3 24 | -101.4% | — | ||
| Q2 24 | -804.4% | — | ||
| Q1 24 | -235203.2% | — |
每股收益（稀释后）ABVCACOG
| Q4 25 | — | $-0.10 | ||
| Q3 25 | $-0.09 | $-0.30 | ||
| Q2 25 | — | $-0.65 | ||
| Q1 25 | — | $-0.13 | ||
| Q4 24 | $-0.02 | — | ||
| Q3 24 | $-0.03 | — | ||
| Q2 24 | $-0.08 | — | ||
| Q1 24 | $-0.29 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $257.2K | $66.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $12.1M | $62.5M |
| 总资产 | $21.2M | $79.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABVCACOG
| Q4 25 | — | $66.0M | ||
| Q3 25 | $257.2K | $35.4M | ||
| Q2 25 | — | $39.4M | ||
| Q1 25 | — | $45.5M | ||
| Q4 24 | $313.1K | — | ||
| Q3 24 | $208.2K | — | ||
| Q2 24 | $200.0K | — | ||
| Q1 24 | $106.4K | — |
股东权益ABVCACOG
| Q4 25 | — | $62.5M | ||
| Q3 25 | $12.1M | $33.9M | ||
| Q2 25 | — | $31.9M | ||
| Q1 25 | — | $40.8M | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $1.6M | — | ||
| Q2 24 | $1.8M | — | ||
| Q1 24 | $1.7M | — |
总资产ABVCACOG
| Q4 25 | — | $79.7M | ||
| Q3 25 | $21.2M | $46.3M | ||
| Q2 25 | — | $45.1M | ||
| Q1 25 | — | $48.6M | ||
| Q4 24 | $7.5M | — | ||
| Q3 24 | $7.8M | — | ||
| Q2 24 | $8.0M | — | ||
| Q1 24 | $8.0M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-964.7K | $-6.9M |
| 自由现金流经营现金流 - 资本支出 | — | $-7.1M |
| 自由现金流率自由现金流/营收 | — | -252.6% |
| 资本支出强度资本支出/营收 | — | 5.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-20.7M |
8季度趋势，按日历期对齐
经营现金流ABVCACOG
| Q4 25 | — | $-6.9M | ||
| Q3 25 | $-964.7K | $-5.3M | ||
| Q2 25 | — | $-6.1M | ||
| Q1 25 | — | $-2.0M | ||
| Q4 24 | $-702.1K | — | ||
| Q3 24 | $60.2K | — | ||
| Q2 24 | $-211.4K | — | ||
| Q1 24 | $-955.8K | — |
自由现金流ABVCACOG
| Q4 25 | — | $-7.1M | ||
| Q3 25 | — | $-5.4M | ||
| Q2 25 | — | $-6.1M | ||
| Q1 25 | — | $-2.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率ABVCACOG
| Q4 25 | — | -252.6% | ||
| Q3 25 | — | -188.8% | ||
| Q2 25 | — | -370.9% | ||
| Q1 25 | — | -72.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度ABVCACOG
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
